Bausch Health Cos Research and Development Expenses 2012-2026 | BHC
Bausch Health Cos research and development expenses from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
|
Bausch Health Cos Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $629 |
| 2024 | $616 |
| 2023 | $604 |
| 2022 | $529 |
| 2021 | $465 |
| 2020 | $452 |
| 2019 | $471 |
| 2018 | $413 |
| 2017 | $361 |
| 2016 | $421 |
| 2015 | $334 |
| 2014 | $246 |
| 2013 | $157 |
| 2012 | $269 |
| 2011 | $66 |
|
Bausch Health Cos Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $163 |
| 2025-12-31 | $161 |
| 2025-09-30 | $166 |
| 2025-06-30 | $159 |
| 2025-03-31 | $143 |
| 2024-12-31 | $163 |
| 2024-09-30 | $146 |
| 2024-06-30 | $156 |
| 2024-03-31 | $151 |
| 2023-12-31 | $152 |
| 2023-09-30 | $153 |
| 2023-06-30 | $156 |
| 2023-03-31 | $143 |
| 2022-12-31 | $142 |
| 2022-09-30 | $133 |
| 2022-06-30 | $127 |
| 2022-03-31 | $127 |
| 2021-12-31 | $117 |
| 2021-09-30 | $121 |
| 2021-06-30 | $115 |
| 2021-03-31 | $112 |
| 2020-12-31 | $119 |
| 2020-09-30 | $103 |
| 2020-06-30 | $108 |
| 2020-03-31 | $122 |
| 2019-12-31 | $114 |
| 2019-09-30 | $123 |
| 2019-06-30 | $117 |
| 2019-03-31 | $117 |
| 2018-12-31 | $120 |
| 2018-09-30 | $107 |
| 2018-06-30 | $94 |
| 2018-03-31 | $92 |
| 2017-12-31 | $90 |
| 2017-09-30 | $81 |
| 2017-06-30 | $94 |
| 2017-03-31 | $96 |
| 2016-12-31 | $174 |
| 2016-09-30 | $20 |
| 2016-06-30 | $124 |
| 2016-03-31 | $103 |
| 2015-12-31 | $-13 |
| 2015-09-30 | $197 |
| 2015-06-30 | $93 |
| 2015-03-31 | $56 |
| 2014-12-31 | $19 |
| 2014-09-30 | $79 |
| 2014-06-30 | $75 |
| 2014-03-31 | $73 |
| 2013-12-31 | $-69 |
| 2013-09-30 | $173 |
| 2013-06-30 | $29 |
| 2013-03-31 | $24 |
| 2012-12-31 | $210 |
| 2012-09-30 | $19 |
| 2012-06-30 | $18 |
| 2012-03-31 | $22 |
| 2011-12-31 | $17 |
| 2011-09-30 | $17 |
| 2011-06-30 | $18 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |